Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? - A case series
| Autor: | Bernhard J. Steinhoff, Marko Blickhan, Patricia Mahn, Jakob Stockinger, Reinhold Kornmeier, Anke M. Staack, Daniel Dietmann, Matthias Bacher, Matthias Schneider, Viviane Bernedo, Tassanai Intravooth, Christoph Kurth |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Brivaracetam Gastroenterology 03 medical and health sciences Epilepsy 0302 clinical medicine Blurred vision Seizures Internal medicine Medicine Humans Adverse effect Oxcarbazepine business.industry Carbamazepine Middle Aged medicine.disease Pyrrolidinones 030104 developmental biology Neurology Tolerability Female Neurology (clinical) Levetiracetam Epilepsies Partial medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Epilepsy research. 159 |
| ISSN: | 1872-6844 |
| Popis: | Brivaracetam (BRV) was recently introduced for the treatment of patients with focal epilepsy. BRV undergoes relatively few interactions, but one of them leads to the elevation of carbamazepine (CBZ)-10,11-CBZ-epoxide (CBZ-E) if BRV is co-administered with CBZ. This interaction has been considered to be clinically negligible. We present a case series of nine patients. In eight of them, levetiracetam (LEV) was switched to BRV. In the remaining case, oxcarbazepine was replaced by CBZ and added to a stable BRV dose. A marked increase of CBZ-E occurred in every case and was associated with clinically relevant symptoms including blurred vision, diplopia, dizziness, or fatigue in three of them. However, in the remaining six, the elevated CBZ-E levels were not associated with any tolerability problems. The importance of CBZ-E for adverse events under CBZ may have been overemphasized in the past and is not clinically impairing in most cases treated with the combination of BRV and CBZ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect